Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Langsenlehner, T; Thurner, EM; Renner, W; Gerger, A; Kapp, KS; Langsenlehner, U.
Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy.
Strahlenther Onkol. 2014; 190(4):364-369 Doi: 10.1007/s00066-013-0503-2
Web of Science PubMed FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Langsenlehner Tanja
Co-Autor*innen der Med Uni Graz
Gerger Armin
Kapp Karin S.
Langsenlehner Uwe
Renner Wilfried
Thurner Eva-Maria

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Vascular endothelial growth factor-A (VEGF-A), a key regulator of tumor-induced angiogenesis, is critical for tumor growth and metastasization. The goal of the present study was to evaluate the prognostic value of VEGF single nucleotide polymorphisms (SNPs) and haplotypes for clinical recurrence after definitive radiotherapy for prostate cancer. The association of seven VEGF-A polymorphisms and their haplotypes with clinical recurrence (defined as the occurrence of local recurrence and/or distant metastases) in 496 prostate cancer patients treated with definitive radiotherapy were investigated. Genotypes were determined by 5'-nuclease (TaqMan) assays; haplotypes were analyzed using the Haploview program. Within a median follow-up time of 80 months, 44 patients (9 %) developed clinical recurrences. Haplotype analysis showed two separate blocks of high-linkage disequilibrium, formed by five polymorphisms (- 2578C > A, - 2489C > T, - 1498C > T, - 634G > C, - 7C > T) upstream of the coding sequence (CCCCC, ATTGC, CCCGC, ATTGT) and two polymorphisms (936C > T, 1612G > A) downstream of the coding sequence (CA, CG, TG). Carriers of at least 1 copy of the ATTGC haplotype were at higher risk of recurrence (hazard ratio [HR] 3.83; 95 %CI 1.48-9.90, p = 0.006); for carriers of 2 copies, the HR was 4.85 (95 %CI 1.72-13.6; p = 0.003). In multivariate analysis, patients harboring at least one copy of the ATTGC haplotype remained at increased risk of recurrence (HR 3.63, 95 %CI 1.38-9.55, p = 0.009); in patients carrying 2 copies, the HR was 4.72 (95 %CI 1.64-13.6, p = 0.004). Our findings indicate that the VEGF-A ATTGC haplotype may predict clinical recurrence in prostate cancer patients treated with radiotherapy.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Aged, 80 and over -
Aged, 80 and over - epidemiology
Disease-Free Survival -
Genetic Association Studies -
Genetic Predisposition to Disease - epidemiology
Genetic Predisposition to Disease - genetics
Genetic Variation - genetics
Heterozygote -
Humans -
Longitudinal Studies -
Male -
Middle Aged -
Neoplasm Recurrence, Local - genetics
Neoplasm Recurrence, Local - mortality
Neoplasm Recurrence, Local - radiotherapy
Polymorphism, Single Nucleotide - genetics
Prevalence -
Prostatic Neoplasms - genetics
Prostatic Neoplasms - mortality
Prostatic Neoplasms - radiotherapy
Risk Factors -
Survival Rate -
Vascular Endothelial Growth Factor A - genetics

Find related publications in this database (Keywords)
Prostate neoplasms
Neoplasm recurrence, local
Vascular endothelial growth factor-A
© Med Uni Graz Impressum